AEON Biopharma Receives Notice of Non-Compliance from NYSE American Due to Stockholders' Equity Deficit

AEON Biopharma received a notice from NYSE American indicating non-compliance with continued listing standards due to a stockholders' equity deficit of approximately $55 million as of December 31, 2025, and losses in three of the last four fiscal years. The company is already under a plan to regain compliance, and this notice is related to previously disclosed compliance status following year-end results.